Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Lupus Erythematosus, Systemic
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate the safety and effects of high-intensity interval training (HIIT) combined with resistance training in patients with systemic lupus erythematosus

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: HIIT combined with resistance training — Patients with SLE will undergo supervised HIIT on an ergometercycle, 4 x 4 minutes interval, (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week. Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week.

Primary Outcomes

  • Aerobic capacity (Baseline, months 3 and 6)
  • Physical capacity (Baseline, months 3 and 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-11-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Collaborators: Swedish Rheumatism Association, Region Örebro County, County Council of Norrbotten, Sweden, Karolinska University Hospital
Principal Investigators:
  • Carina M Boström, Dr (PRINCIPAL_INVESTIGATOR) - Karolinska Institutet
Contact Information
Study Contact:
Carina M Boström, Dr
046 0722006321
carina.bostrom@ki.se
Ioannis Parodis, Dr
046 0722321322
ioannis.parodis@ki.se
Carina M Boström, Dr
046 0722006321
carina.bostrom@ki.se
Carina Boström
Interventions
  • Behavioral: HIIT combined with resistance training — Patients with SLE will undergo supervised HIIT on an ergometercycle, 4 x 4 minutes interval, (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week. Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week.
Study Locations (1 sites)
Carina Boström, Stockholm, Huddinge 141 83 Sweden
Eligibility Criteria
Inclusion Criteria: * ≥18 years old * Fulfilment of the 1982 American College of Rheumatology (ACR) criteria; or 2012 Systemic Lupus International Collaborating Clinics (SLICC/ACR-Damage Index (DI)) classification criteria; or EULAR/ACR criteria; or patients that have received the diagnosis SLE on clinical grounds * Low to moderate disease activity, for example defined as a score of ≤5 in the clinical version of the SLE Disease Activity Index 2000 (SLEDAI-2K), i.e., excluding the serological descriptors (anti-dsDNA positivity and low complement levels) * Low/minimal or no organ damage, for example defined as a score of ≤3 in the SLICC/ACR DI * Stable pharmacological treatment * The ability to perform a maximal ergometercycle exercise test * Be able to read and understand Swedish Exclusion Criteria: * Symptoms or signs of cerebro-vascular disease, pulmonary embolus, pulmonary hypertension, pulmonary fibrosis, cardiovascular disease, angina pectoris, myocardial infarction, dyspnea at rest, uncontrolled blood pressure and uncontrolled diabetes within one year prior to study entry. Chronic kidney disease with * Patients who fulfil the absolute contraindications for maximal exercise testing according to American Heart Association * Patients who cannot perform a maximal ergometercycle exercise test due to the disease * Diseases or other conditions that strongly reduce the ability to exercise or that exercise is not recommended * Patients who perform regular aerobic fitness training and muscle strength exercise sessions at fixed times, \>1 time/week * Pregnancy
Conditions Depressive Disorder, Major
Phase NA
Enrollment 165
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

A large body of evidence on depression heterogeneity point to an "immunometabolic" subtype characterized by the clustering of immunometabolic dysregulations with atypical behavioral symptoms related to energy homeostasis. Motivational and motor impairments reflected by symptoms of anhedonia and psychomotor retardation in major depression are closely related to alterations in energy homeostasis, are associated with increased inflammation, and may be a direct consequence of the impact of inflammatory cytokines on the dopamine system in the brain. In the proposed project, the investigators will examine the effect of dopamine stimulation on motivation and motor function in patients with major depression and healthy controls and the role of inflammation using a double-blind, randomized, placebo-controlled, cross-over design. If successful, this study would provide crucial evidence that pharmacologic strategies that increase dopamine may effectively treat inflammation-related symptoms of anhedonia and psychomotor retardation in major depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Drug: L-dopa/Carbidopa — Patients and healthy controls will receive one time administration of L-dopa/Carbidopa (100/25 mg).
  • Drug: Placebo — Patients and healthy controls will receive one time administration of Placebo.

Primary Outcomes

  • The change in response bias (logb) after L-dopa/Carbidopa compared to placebo in the Probabilistic Reward Task (PRT). (All participants will be tested on two separate experimental sessions separated by an interval of 48 hours, after L-dopa/Carbidopa or placebo.)
  • The change in mean gait speed [m/s] after L-dopa/Carbidopa compared to placebo in the dual task. (All participants will be tested on two separate experimental sessions separated by an interval of 48 hours, after L-dopa/Carbidopa or placebo.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-26
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 165 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Charite University, Berlin, Germany
Collaborators: Prof. Dr. Stefan M. Gold, Prof. Dr. Soyoung Q Park, Dr. Ulrike Grittner, Motognosis GmbH
Principal Investigators:
  • Woo Ri Chae, MD MSc (PRINCIPAL_INVESTIGATOR) - Charite University, Berlin, Germany
Contact Information
Study Contact:
Woo Ri Chae, MD MSc
+49 30 450 517625
woo-ri.chae@charite.de
Woo Ri Chae, MD MSc
030 450 517625
motivade-studie@charite.de
Klinik für Psychiatrie und Psychotherapie
Interventions
  • Drug: L-dopa/Carbidopa — Patients and healthy controls will receive one time administration of L-dopa/Carbidopa (100/25 mg).
  • Drug: Placebo — Patients and healthy controls will receive one time administration of Placebo.
Study Locations (1 sites)
Klinik für Psychiatrie und Psychotherapie, Steglitz, 12203 Germany
Eligibility Criteria
Inclusion Criteria: For patients with major depressive disorder: * diagnosis of major depressive disorder according to DSM-5 * free of antidepressant medication For healthy participants: * C-reactive protein (CRP): ≤ 1 mg/l * free of antidepressant medication * free of any current psychiatric disorder Exclusion Criteria: * diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, dementia, and current/past alcohol or drug dependence * central nervous system diseases * neurological diseases * suspicious undiagnosed skin lesions or a history of melanoma * narrow-angle or wide-angle glaucoma * bronchial asthma * history of peptic ulcer disease * history of seizures * any severe somatic disease * current infections or chronic inflammatory diseases (e.g., rheumatic diseases, inflammatory bowel disease) * pregnancy / breast-feeding * class 3 obesity (body mass index of 40 or higher) * Use of medication containing reserpine (certain antihypertensive agents), tricyclic antidepressants, bon-selective monoamine oxidase (MAO) inhibitors, antiparkinsonian drugs, sympathomimetic drugs, tetrabenazine.
Conditions Major Depressive Disorder
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken before dosing and following dosing at several timepoints up to 5 weeks post-dosing.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Psilocybin — Psilocybin, 25mg, given once orally.
  • Drug: Pimavanserin — Pimavanserin, 34mg, given once orally
  • Drug: Placebo — Matching placebo.

Primary Outcomes

  • Mystical Experience Questionnaire (MEQ-30) Score (6 hours post-treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-25
Completion: 2028-03-01
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Principal Investigators:
  • James Murrough (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
  • Rachel Fremont (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
Contact Information
Study Contact:
Depression and Anxiety Center Icahn School of Medicine at Mount Sinai
(212) 241-6539
dac@mssm.edu
Depression and Anxiety Center
212-241-6539
dac@mssm.edu
Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research
James Murrough
Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research
Interventions
  • Drug: Psilocybin — Psilocybin, 25mg, given once orally.
  • Drug: Pimavanserin — Pimavanserin, 34mg, given once orally
  • Drug: Placebo — Matching placebo.
Study Locations (1 sites)
Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York, New York 10025 United States
Eligibility Criteria
Inclusion Criteria: * Age 21-80 years, any gender * Current primary diagnosis of Unipolar Major Depressive Disorder (MDD) without psychotic features using DSM-5 criteria * 24-item Hamilton Rating Scale for Depression (HRSD) ≥16 * Current diagnosis of Major Depressive Episode (MDE) * Capable of providing informed consent and complying with study procedures * Currently using or agreeing to use a highly effective contraception, if person of childbearing potential (such as condoms, IUD, or oral contraceptive), for duration of the study. Male participants agree to use highly effective contraception with partners of childbearing potential * Discontinuation of any serotonergic drug for at least 2 weeks or 5 half-lives (whichever of the two is longer) prior to psilocybin exposure Exclusion Criteria: * Any severity of substance use disorder in the last 6 months (excluding tobacco use disorder) as determined by DSM-V criteria via the SCID * Current psychiatric hospitalization or psychiatric hospitalization within the last 6 months * Use of psychedelics in the last 12 months * Non-medical or illicit use of ketamine in the past 12 months * Negative reaction after prior use of psychedelics * Past or current psychotic disorder (including psychotic MDD), mania, or bipolar disorder * Severe depression as indicated by Clinical Global Impressions (CGI)-Severity score ≥ 5 at baseline * Significant suicidal ideation as indicated by C-SSRS \> 2 in the past 6 months at time of screening * Suicide attempt in the past 2 years, or clinician concern that the patient poses a risk to self or others * Acute, severe, or unstable medical illness * Weight \> 300 lbs., or girth size incompatible with scanner bore * Any conditions/qualities that make participation in MRI imaging unsafe\* * Any physical or intellectual disability adversely affecting ability to complete assessments. * Current pregnancy or currently breast feeding. * Any clinically significant abnormal lab test result, including clinically significant abnormal baseline liver and/or renal function tests * Currently being treated with a contraindicated medication. Contraindicated medications include antipsychotic medications, serotonergic antidepressant medications, and mood stabilizers that may attenuate the effects of psilocybin. Strong CYP3A4 inhibitors and inducers are also contraindicated. UGT1A9 and UGT1A10 inhibitors, monoamine oxidase, and aldehyde or alcohol dehydrogenase inhibitors are prohibited concomitant medications. * History of abnormal QT prolongation or QTc interval \>450 ms on screening * Use of medications known to prolong the QT interval * Any congenital prolongation of the QT interval or a family history of long QT syndrome * A family history of sudden cardiac or unexplained death * A family history in a first-degree relative of psychosis/schizophrenia or related disorders * A first-degree family history of bipolar disorder * A history of cardiac arrhythmias or who require treatment with an antiarrhythmic medication * A history of any cardiovascular disorder/condition known to increase the possibility of QT prolongation, or any other risk factors for prolonged QT interval/tosades de pointes (including symptomatic bradycardia, hypokalemia, hypomagnesemia, hypocalcemia, heart failure, or Brugada Syndrome) * Preexisting cardiovascular conditions, including cardiac valvulopathy, pulmonary hypertension, hypertension, tachycardia, and any cardiovascular conditions that may be worsened/exacerbated by elevated blood pressure or heart rate. * Baseline vital sign parameters at screening and on day of dosing prior to dose that exceed to the following values for systolic blood pressure (SBP), diastolic (DBP), and heart rate (HR): SBP \> 139 mmHg, DBP 89 mmHg, and HR \> 90 bpm * Hypersensitivity to either psilocybin or pimavanserin * Psychiatric or other condition judged to be incompatible with establishment of rapport with therapy team and/or safe exposure to psilocybin * Positive urine toxicology at screening * Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) * Mini-Mental State Examination (MMSE) score \< 25 * Brief Psychiatric Rating Scale (BPRS-6) \> 5 * Potential fall risk
Conditions Stress Disorders, Post-Traumatic, Premat...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized controlled trial of a dyad-centered, doula support and healthcare coordination model of care in a large urban neonatal intensive care unit (NICU), which serves a high-risk, low-income, majority Black population. In addition to doula support and coordination of care in the NICU, there will be a warm handoff to a community doula to continue the support once infants leave the Hospital of the University of Pennsylvania (HUP) NICU.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Doula Support — Doula support including care coordination to mental and medical health services in the NICU, with a warm handoff to a community doula to continue the support once infants leave the HUP NICU.

Primary Outcomes

  • Difference in Post Traumatic Stress Disorder Scores at 6 months postpartum (6 months)
  • Number of participants who have attendance with a primary care provider by 6 months postpartum (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-11
Completion: 2027-08
Eligibility
Age: 16 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pennsylvania
Principal Investigators:
  • Heather Burris, MD MPH (PRINCIPAL_INVESTIGATOR) - University of Pennsylvania
Contact Information
Study Contact:
Heather Burris, MD MPH
(215) 573-4916
Burrish@chop.edu
Niesha Darden
dardenn2@chop.edu
Heather Burris, MD MPH
(215) 573-4916
burrish@chop.edu
Hospital of the University of Pennsylvania
Interventions
  • Other: Doula Support — Doula support including care coordination to mental and medical health services in the NICU, with a warm handoff to a community doula to continue the support once infants leave the HUP NICU.
Study Locations (1 sites)
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: * HUP postpartum patients who are at least 16 years old at the time their newborns' birth * Infant born at HUP * Preterm birth \<34 weeks * English language speaking Exclusion Criteria: * Unable to read or sign informed consent * Parents of infants transferred into HUP NICU * If the medical team believes that the infant may not live or be transferred to another hospital in upcoming weeks * HUP postpartum patients who are less than 16 years of age at the time of their newborns' birth
Conditions Major Depressive Disorder
Phase Not Applicable
Enrollment 228
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Device: Aversive stimuli — Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
  • Drug: PET radiotracer — A Nociceptin/Orphanin FQ ("N/OFQ") peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels.

Primary Outcomes

  • Clinical Interview (Baseline)
  • Behavioral Performance on the Probabilistic Reward Task (PRT) (Baseline)
  • MRI Data (within 30 days of Screening Visit)
  • Salivary Cortisol (Baseline)
  • PET Data (within 30 days of Screening Visit)
  • Arterial blood data (Baseline)
  • Follow-up Clinical Interviews (Change from Baseline at 6 months and 12 months after the PET visit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-12-29
Completion: 2027-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 228 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mclean Hospital
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Diego Pizzagalli, PhD (PRINCIPAL_INVESTIGATOR) - Mclean Hospital
Contact Information
Study Contact:
Tracy Lam, BS
617-855-4437
mclrew41study@mgb.org
David Crowley, ALM
617-855-4432
djcrowley@mclean.harvard.edu
Tracy Lam, BS
617-855-4437
clam@mclean.harvard.edu
McLean Hospital
Interventions
  • Device: Aversive stimuli — Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
  • Drug: PET radiotracer — A Nociceptin/Orphanin FQ ("N/OFQ") peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels.
Study Locations (1 sites)
McLean Hospital, Belmont, Massachusetts 02478 United States
Eligibility Criteria
Inclusion Criteria for all participants: * All genders, races, and ethnic origins, aged between 18 and 45 * Capable of providing written informed consent, and fluent in English * Right-handed * Absence of any psychotropic medications for at least 2 weeks * Has a smartphone (iPhone or Android) (needed for Ecological Momentary Assessment) Inclusion Criteria for "Remitted MDD" group: * Meets inclusion criteria for all subjects, plus: * History of MDD as defined by DSM-5 * Absence of anxiety disorder for the past two months Inclusion Criteria for "Current MDD" group: * Meets inclusion criteria for all subjects, plus: * Presence of MDD as defined by DSM-5 * Absence of anxiety disorder for the past two months Exclusion Criteria for all participants: * Subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician. These patients will be immediately referred to appropriate clinical treatment * Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, IUD, s/p tubal ligation, or partner with vasectomy) * Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease * History of seizure disorder * History of psychiatric illnesses, other than depression or anxiety disorders among the Current MDD and Remitted MDD groups * History of substance use disorder or alcohol use disorder (as these terms are defined by DSM-5); except depressed subjects may have a history of 'Mild' substance/alcohol use disorder only if it ended as least 12 months ago * History of cocaine or stimulant use or dopaminergic drugs * History or current diagnosis of dementia, or a score of \< 26 on the Mini Mental State Examination at the screening visit; * Patients with mood congruent or mood incongruent psychotic features * Current use of other psychotropic drugs * Clinical or laboratory evidence of hypothyroidism * Patients with a lifetime history of electroconvulsive therapy (ECT) * Failure to meet standard MRI safety requirements * Abnormal ECG and lab results * History of seizure disorder * Contraindications for arterial line (e.g., abnormal result on Allen test, Raynaud's syndrome, history of anemia or bleeding disorder, history of fainting from blood draws).

Nephrospec Switzerland

NCT06194591
Recruiting
Conditions Chronic Kidney Diseases, Hypertension
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, double-blind sham-controlled monocentric trial. 30 patients that are diagnosed with hypertension and with moderate to severe chronic kidney disease are included in this trial. 20 of them are randomized into the active treatment arm, 10 into the sham arm. Low-intensity extracorporal shock wave (Li-ESWT) sessions (arm1) or sham sessions (arm2), will be administered with a dedicated probe within three consecutive weeks to the kidneys of patients.The study will add data to the effects of the shock wave treatment on blood pressure and will assess whether this treatment improves renal function, perfusion and oxygenation. The study includes a third arm (arm3) in which treatment sessions are administered to patients that were in the placebo group in the first phase of the study (arm2).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: NephrospecTM, low-intensity extracorporal shockwave therapy device — Patients will receive 6 Li-ESWT treatments with the NephrospecTM device over three consecutive weeks, with a minimal recess of 24 hours between treatments and a maximum of 3 sessions per week. Three hundred shockwaves will be applied by the PI or co-PI to each one of 8 pre-selected regions of each kidney, under ultrasound control, with the patient in the prone position. No local anaesthesia is needed. Total treatment time of one session is 30 minutes. The participant will remain under supervision for another 30 minutes and will be discharged hereafter.
  • Device: Sham-Device — The sham device is the NephrospecTM applicator with an internal barrier to prevent shockwaves to pass through to the patient.

Primary Outcomes

  • Systolic 24-hour ambulatory blood pressure (ABPM) (Baseline to 12-weeks (-1/+3weeks) Follow-up post last treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-19
Completion: 2029-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Menno Pruijm
Principal Investigators:
  • Menno Pruijm, Dr (PRINCIPAL_INVESTIGATOR) - CHUV
Contact Information
Study Contact:
Menno Pruijm, Dr
+41 (0)21 314 13 58
menno.pruijm@chuv.ch
Wendy Brito
Wendy.Brito@chuv.ch
Menno Pruijm, Dr
0041795565946
menno.pruijm@chuv.ch
Department of Nephrology, Centre Hospitalier Universitaire Vaudois
Interventions
  • Device: NephrospecTM, low-intensity extracorporal shockwave therapy device — Patients will receive 6 Li-ESWT treatments with the NephrospecTM device over three consecutive weeks, with a minimal recess of 24 hours between treatments and a maximum of 3 sessions per week. Three hundred shockwaves will be applied by the PI or co-PI to each one of 8 pre-selected regions of each kidney, under ultrasound control, with the patient in the prone position. No local anaesthesia is needed. Total treatment time of one session is 30 minutes. The participant will remain under supervision for another 30 minutes and will be discharged hereafter.
  • Device: Sham-Device — The sham device is the NephrospecTM applicator with an internal barrier to prevent shockwaves to pass through to the patient.
Study Locations (1 sites)
Department of Nephrology, Centre Hospitalier Universitaire Vaudois, Lausanne, Canton of Vaud 1011 Switzerland
Eligibility Criteria
Inclusion Criteria: * Age: 18 years to 82 years. * Patient is diagnosed with Hypertension, i.e. home,office and/or 24h systolic blood pressure ≥135 mmHg (as per ISH guidelines, 2020), currently on stable (over 60 days) medical therapy as prescribed by a physician, of none, one, or more antihypertensive medication classes. Patients will be considered stable if no relevant medication change for over 60 days or for 30 days if there were no previous changes 90 days before the current change. * Patients diagnosed with moderate to severe chronic renal failure (eGFR 20-70 mL/min/1.73m2) who are currently on stable medical therapy as prescribed by a physician. * Patients with eGFR between 60-90 ml/min/1.73m2 and albuminuria \>=30mg/mmol in spot urine or \>=300mg/day in 24h urine collection * Patient is able and willing to comply with the required follow-up schedule. * Patient is capable of giving an informed consent. Exclusion Criteria: * Hypertension: Individual's systolic BP is over 180mmHg when receiving stable medical medication regimen as prescribed by a physician, of none, one, or more antihypertensive medication classes at maximally tolerated dose. Hypertension secondary to an identifiable and treatable cause, other than Renal artery stenosis or CKD, or is prescribed a medication that may raise BP. * History of previous renal artery stent. Stent or other intervention involving renal arteries including but not limited to renal denervation procedures. * Kidney conditions non compatible with the study: Patient has an eGFR \<20 ml/min/1.73m², is on Dialysis or has had a kidney transplant performed. Active pyelonephritis. History of or current kidney stones. Patients with polycystic kidney disease or a known complicated renal cyst (Bosniak III or higher). * Symptomatic patients (Macrohematuria) with a decrease of over 2 grams in Hb. * Hemoglobin (Hb) ≤ 9 grams per deciliter (blood). * Coagulation issues: Bleeding tendency resulting from hematologic disease. Subjects having INR \> 2.5 and PT, PTT and platelet count which deviates from the clinical laboratory normal reference range. * Diseases non compatible with the study: Recent (less than 6 months) history of myocardial infarction, PCI, stroke or hospitalization for HFrEF (heart failure with reduced ejection fraction). Individual has type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1c \> 10%). * Active Cancer - primary tumor or metastatic, such as liver, renal, testicular, abdominal tumor or local tumor at treatment area.. * Treatment non compatible with the study: Patients that have been treated with immunosuppression in the last 3 months. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea. No change in dosing of RAS inhibitors in the month prior to the procedure is required. * Technical impossibility to participate: Local infection of the skin at the area to be in contact with the applicator. * Known allergy to Sonovue® contrast product (hypersensibility to sulfur hexyfluoride or another component). * No other contraindication to SonoVue, ie. patients with right-to-left shunts, severe pulmonary hypertension (pulmonary arterial pressure \> 90 mm Hg), uncontrolled systemic hypertension and in adult patients with respiratory distress syndrome (ARDS). * Contraindication to undergo MR-imaging such as the presence of a pacemaker or other implanted metallic device or severe claustrophobia. * Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject/ Unable to obtain consent * Known or suspected non-compliance, drug or alcohol abuse * Individual works night shifts. * Individual is pregnant, breast feeding or planning to become pregnant. * Individual does not want to be informed in case of accidental finding related to individual's health discovered during imaging or other study-related exams. * Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation, * Previous enrolment into the current investigation, * Enrolment of the PI, his/her family members, employees, and other dependent persons
Conditions Hypertension
Phase NA
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

WEAVE NM (Wide Engagement for Assessing Vaccine Equity in New Mexico) is a community-based research initiative working to improve health outcomes in underserved populations, with a current focus on hypertension and food justice. The project centers on the lived experiences of Native American, African American, Hispanic/Latino, and Asian American residents in Albuquerque's International District and South Valley. With guidance from community voices and ongoing collaboration with local organizations, health providers, and residents, the initiative integrates cultural values, public policy, and social realities into solutions that promote equity and wellness. As part of this work, a clinical trial is being conducted through First Nations Community HealthSource (FNCH) to evaluate a culturally tailored blood pressure intervention called Heart Health and Nutrition for Life (HHNL). The trial includes patients who receive standard hypertension care and blood pressure self-monitoring, with one group also participating in a community health worker-led educational program in their first six months of study enrollment. This curriculum addresses healthy eating, physical activity, medication adherence, stress reduction, and avoidance of alcohol and tobacco, all delivered with cultural sensitivity and community insight. After six months, the groups switch roles, allowing all participants to receive the education component. Participants' progress is measured over a 12-month period by tracking changes in blood pressure, cholesterol, weight, blood sugar (HbA1c), and emotional well-being. The aim is to determine whether this community-supported approach improves outcomes more effectively than standard care alone with blood pressure self-monitoring. This study represents a broader effort to create long-term, community-rooted solutions to chronic health issues by addressing the social and environmental factors that influence well-being. For individuals living in the International District or South Valley, this project offers the opportunity to take part in research that respects cultural identity and prioritizes real-world impact on health. Interested patients and families can contact their provider at FNCH to learn more about participation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Heart Health and Nutrition for Life (HHNL) — The CHW-led educational intervention will draw on two evidence-based programs, Healthy for Life (American Heart Association) and Your Heart, Your Life (NHLBI). Both curricula are designed to be facilitated by community health workers/promotores de salud and have been tested in both English and Spanish. Study-adapted curricular elements will include 12 core educational activities, delivered in six, two-hour, in-person sessions. In the context of expected family and work obligations alongside limited resources of FNCH patients, the investigators anticipate structuring sessions over, at most, 2 months with a class size of approximately 5-15 patients. In the CHW-led educational intervention, participants will learn about topics such as understanding risk for heart disease, the importance of physical activity, affordable healthy eating, and how family members can support health.
  • Behavioral: Self-Measured Blood Pressure — Self-measured blood pressure (SMBP) is a proven, cost-effective strategy to improve blood pressure control by promoting patient engagement and medication adherence. All study participants will receive the same validated BP monitor, with cuff sizes adjusted as needed, selected from the US Blood Pressure Validated Device Listing. Patients will be trained using the AMA's 7-Step SMBP Quick Guide, consistent with FNCH clinical education practices. They will be asked to record baseline BP readings and complete at least one SMBP cycle per month during the 12-month study. Each cycle includes at least three consecutive days of morning and evening BP measurements.

Primary Outcomes

  • Systolic Blood Pressure (Baseline measurement and at about 3-, 6-, and 12- month timepoints)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-21
Completion: 2027-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of New Mexico
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Westat
Principal Investigators:
  • Tassy Parker, PhD, RN (PRINCIPAL_INVESTIGATOR) - University of New Mexico
  • Linda Son-Stone, Ed D, MPH (PRINCIPAL_INVESTIGATOR) - First Nations Community HealthSource
  • Lisa Cacari Stone, PhD, MS, MA (PRINCIPAL_INVESTIGATOR) - University of New Mexico
Contact Information
Study Contact:
Blake Boursaw, MS
505-925-4377
bboursaw@salud.unm.edu
Tassy Parker, PhD, RN
505-272-4100
TaParker@salud.unm.edu
Nicole Tsosie
505-705-3349
Nichole.Tsosie@fnch.org
First Nations Community HealthSource
Interventions
  • Behavioral: Heart Health and Nutrition for Life (HHNL) — The CHW-led educational intervention will draw on two evidence-based programs, Healthy for Life (American Heart Association) and Your Heart, Your Life (NHLBI). Both curricula are designed to be facilitated by community health workers/promotores de salud and have been tested in both English and Spanish. Study-adapted curricular elements will include 12 core educational activities, delivered in six, two-hour, in-person sessions. In the context of expected family and work obligations alongside limited resources of FNCH patients, the investigators anticipate structuring sessions over, at most, 2 months with a class size of approximately 5-15 patients. In the CHW-led educational intervention, participants will learn about topics such as understanding risk for heart disease, the importance of physical activity, affordable healthy eating, and how family members can support health.
  • Behavioral: Self-Measured Blood Pressure — Self-measured blood pressure (SMBP) is a proven, cost-effective strategy to improve blood pressure control by promoting patient engagement and medication adherence. All study participants will receive the same validated BP monitor, with cuff sizes adjusted as needed, selected from the US Blood Pressure Validated Device Listing. Patients will be trained using the AMA's 7-Step SMBP Quick Guide, consistent with FNCH clinical education practices. They will be asked to record baseline BP readings and complete at least one SMBP cycle per month during the 12-month study. Each cycle includes at least three consecutive days of morning and evening BP measurements.
Study Locations (1 sites)
First Nations Community HealthSource, Albuquerque, New Mexico 87108 United States
Eligibility Criteria
Inclusion Criteria: * Currently a FNCH patient or are willing and able to become a FNCH patient * Current diagnosis of hypertension that was not onset due to pregnancy * Able to speak and read English or Spanish * Cognitively and physically able to independently understand and complete study procedures and provide written informed consent * Self-report at least one systolic blood pressure reading of 130 or greater in the last six months OR show a systolic blood pressure reading of 130 or greater in baseline screening * Live in and receive mail in Albuquerque, New Mexico Exclusion Criteria: * By design, adults unable to consent, individuals not yet adults, and prisoners will not be included in this study. * Patients who self-report pregnancy will be automatically excluded from the study. While the investigators are not systematically screening for pregnancy throughout the study, if an individual self-reports pregnancy during the study, they will be withdrawn from study participation and offered the opportunity to re-join the study once no longer pregnant, if activities are still available, following general study procedures. * Individuals who are not able to complete study procedures due to mental or behavioral health conditions, incarceration, or inability to physically bear an arm cuff will also be excluded from the study.
Conditions Sacubitril/Valsartan, Hypertension, Obes...
Phase Not Applicable
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to investigate the effect of sacubitril/valsartan on cardiac function assessed by cardiac magnetic resonance (CMR) in hypertensive patients stratified by BMI.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Drug: Sacubitril / Valsartan Oral Tablet [Entresto] — There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.
  • Drug: ACEI/ARB — There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group. Including: benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan.

Primary Outcomes

  • Changes on left ventricular ejection fraction (LVEF) (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-09-01
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Friendship Hospital
Principal Investigators:
  • Rongchong Huang, M.D. (PRINCIPAL_INVESTIGATOR) - Beijing Friendship Hospital
Contact Information
Study Contact:
Rongchong Huang, M.D.
+86-13811039417
rchuang@ccmu.edu.cn
Rongchong Huang, M.D.
+86-13811039417
rchuang@ccmu.edu.cn
Beijing Friendship Hospital, Capital Medical University
Rongchong Huang, M.D.
Beijing Friendship Hospital, Capital Medical University
Interventions
  • Drug: Sacubitril / Valsartan Oral Tablet [Entresto] — There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.
  • Drug: ACEI/ARB — There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group. Including: benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan.
Study Locations (1 sites)
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing Municipality 100050 China
Eligibility Criteria
Inclusion Criteria: * Patients with essential hypertension * 18-70 years old * No major barriers to provide written consent Exclusion Criteria: * Secondary hypertension, except because of sleep apnea * cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months * Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases) * Unable to understand or comply with the study procedures
Conditions Adherence to Glaucoma Therapy
Phase Not Applicable
Enrollment 200
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this real-life, national, multicentre, prospective clinical investigation is to describe the adherence rate over time in patients with glaucoma or OHT already treated with IOP-lowering eye drops using connected device CONNECTDROP® The main questions it aims to answer are: * The mean annual adherence rate, defined as the percentage of the prescribed doses taken by the patient * The adherence profile of each patient * The association between the adherence profile, the objective adherence data and the clinical data. Participants will use the connected device CONNECTDROP® associated with the smartphone application on a daily basis.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Adherence rate over time in patients with glaucoma or OHT already treated with IOP-lowering eye drops in EASYGRIP® bottle clipped with CONNECTDROP® (From enrollment to the end of the study at 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-19
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Laboratoires Thea
Contact Information
Study Contact:
Medical Operation Manager
+33 4 73 98 14 36
Fabienne.HESKIA@theapharma.com
Gian Luca Laffi
Studio Oculistico D'Azeglio
Marco Di Maita
Centro Medico Polispecialistico Di Maita
Interventions
N/A
Study Locations (15 sites)
Studio Oculistico D'Azeglio, Bologna, 40100 Italy
Centro Medico Polispecialistico Di Maita, Catania, Italy
Studio Medico Oculistico Dr.ssa Rosa SCHIAVELLI s.r.l., Corigliano, Italy
Ospedale Policlinico S. Martino-IRCCS Clinica Oculistica Università di Genova, Genova, 16132 Italy
Centro Corporis Lab, Lecce, 73100 Italy
Studi Oculistici - Dott. Andrea Bedei, Lucca, 55047 Italy
Poliambulatorio Chirurgico Modenese Eyecare Clinic, Modena, Italy
Centro Oculistico Ramovecchi S.r.l., Morrovalle, 62010 Italy
Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, Università degli studi di Napoli Federico II, Naples, Italy
UOSD di Oculistica, Fondazione PTV Policlinico Tor Vergata, Roma, 00133 Italy
Eligibility Criteria
Inclusion Criteria: * Adult patient (≥ 18 years old), man or woman * Patient with a diagnosis of bilateral open angle glaucoma or OHT * Patients being prescribed with glaucoma eye drops in EASYGRIP® bottle for at least 6 weeks in monotherapy. * Patient willing to participate in the study * Patient who consents for data collection in the frame of the study Exclusion Criteria: * Pregnant and/or lactating woman * Patient receiving another ocular treatment for a chronic condition (i.e. regular instillations for several months) * Protected patient: adult under guardianship, curatorship or other protection legal, deprived of liberty by judicial or administrative decision
Conditions Prehypertension (Elevated Blood Pressure...
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

In this study, the investigators will evaluate acute changes in vascular function measures after moderate-intensity continuous and high-intensity interval exercise in healthy and prehypertensive individuals. Participants will be subjected to three separate visits: control condition (30 min rest), moderate-intensity continuous exercise, and high-intensity interval exercise. The investigators will measure aerobic capacity using a cardiopulmonary exercise test (CPET) using indirect gas-exchange to derive subsequent exercise intensity and maximal oxygen uptake. The investigators will evaluate different measures of vascular function (Pulse-wave velocity, Flow-mediated slowing, microvascular function) before and after each condition. The study will involve two groups of participants: healthy individuals and prehypertensive individuals. The investigators aim to establish the reliability and validity of less-established methods of vascular function assessment (flow-mediated slowing and microvascular function) against established measures (pulse-wave velocity). The acute response of vascular function to different exercise intensities has not yet been thoroughly researched using the aforementioned measures in individuals with similar characteristics to the proposed study cohort.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Screening Masking/blinding: Double

Interventions / Regimen

  • Other: Control-no treatment — 30 minutes of rest
  • Other: Exercise — 30 minutes of Moderate-Intensity Continuous Exercise
  • Other: Exercise — 30 minutes of High-Intensity Interval Exercise

Primary Outcomes

  • Arterial stiffness (At the beginning of each visit (T0) and immediately after each acute stimulus (T1))
  • Microvascular function (At the beginning of each visit (T0) and immediately after each acute stimulus (T1))
  • Flow-mediated slowing (At the beginning of each visit (T0) and immediately after each acute stimulus (T1))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-24
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Ljubljana
Contact Information
Study Contact:
Armin H Paravlic, PhD
+386015207840
armin.paravlic@fsp.uni-lj.si
Simon Iskra, MSc
0038670439447
simon.iskra@fsp.uni-lj.si
University of Ljubljana, Faculty of sport
Interventions
  • Other: Control-no treatment — 30 minutes of rest
  • Other: Exercise — 30 minutes of Moderate-Intensity Continuous Exercise
  • Other: Exercise — 30 minutes of High-Intensity Interval Exercise
Study Locations (1 sites)
University of Ljubljana, Faculty of sport, Ljubljana, 1000 Slovenia
Eligibility Criteria
Inclusion Criteria: Normotensive participants inclusion criteria: * 18 - 50 years of age, BMI \< 30, blood pressure (BP) within the optimal range according to the latest ESH guidelines (\< 120 mmHg systolic and/or \< 80 mmHg diastolic BP) * Sedentary or low active according to the Global Physical Activity Questionnaire (GPAQ) (Armstrong \& Bull, 2006; Lim et al., 2012) * No prescribed medication and absence of chronic diseases Inclusion criteria for prehypertensive individuals: * 18 - 50 years of age, BMI \< 30 * Diagnosed prehypertension by a clinican from the Hypertension clinic, University clinical centre of Ljubljana using established criteria * Sedentary or low or moderately active according to the Global Physical Activity Questionnaire (GPAQ) * No prescribed medication and absence of chronic diseases Exclusion Criteria: * Blood pressure out of the optimal range (normotensives) * High level of phyisical activity (moderate or high active according to GPAQ) * Hypotension * Chronic diseases * Prescribed medication * Lower extremity injury in the last six months * Menopause * Absence of normal menstrual cycle * Pregnancy * Smoking
Conditions Glaucoma
Phase Not Applicable
Enrollment 249
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The specific aims of the clinical studies are to: * Develop a directional high-resolution OCT and OCT angiography prototype to improve imaging of structure and perfusion. * Validate wide-field OCT and OCT angiography parameters to improve early glaucoma detection. * Simulate visual field results by combining structural and angiography OCT data. * Assess abilities of above technologies and OCT-derived parameters on predicting glaucoma detection, conversion, and progression.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Measure of retinal non-perfusion areas in mm2 (5 years)
  • Measure vessel density in percentage (%) (5 years)
  • Determine accuracy of sector visual field progression in OCT-based sector visual field simulation compared to actual visual field results. Measured in dB change over time. (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2013-09-25
Completion: 2031-05-31
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: true
Enrollment: 249 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oregon Health and Science University
Collaborators: National Eye Institute (NEI)
Principal Investigators:
  • Aiyin Chen, MD (PRINCIPAL_INVESTIGATOR) - Oregon Health and Science University
Contact Information
Study Contact:
Chinmay Deshpande, M.Optom.
503-494-9628
deshpanc@ohsu.edu
Denzil Romfh, OD
503-494-4351
romfhd@ohsu.edu
Chinmay Deshpande, M.Optom.
503-494-9628
deshpanc@ohsu.edu
Oregon Health & Science University, Casey Eye Institute
Interventions
N/A
Study Locations (1 sites)
Oregon Health & Science University, Casey Eye Institute, Portland, Oregon 97214 United States
Eligibility Criteria
Inclusion Criteria: Normal Subjects (both eyes must meet all criteria) 1. No history or evidence of retinal pathology or glaucoma 2. Normal Humphrey 24-2 VF: A mean defect (MD), corrected pattern standard deviation (CPSD) within 95% limits of normal reference, and glaucoma hemifield test (GHT) within normal limits (97%). 3. Intraocular pressure \< 21 mm Hg 4. Central corneal pachymetry \> 500 microns 5. No chronic ocular or systemic corticosteroid use 6. Open angle (gonioscopy must show 75% or more of the angle to be Grade 2 or more by Shaffer's grading system) 7. Normal appearing ONH and NFL: vertical and horizontal cup/disc ratio (CDR) ≤ 0.5 and intact neuroretinal rim without peripapillary hemorrhages, notches, localized pallor, or NFL defect 8. Symmetric ONH between left and right eyes: CDR difference \< 0.2 in both vertical and horizontal dimensions Inclusion criteria: Glaucoma Group 1. ONH or NFL defect visible on slit-lamp biomicroscopy defined as one of following: 1. diffuse or localized thinning of the rim 2. disc (splinter) hemorrhage 3. notch in the rim 4. vertical cup/disc ratio greater than the fellow eye by \> 0.2 2. Presence or absence of VF defects as measured by Humphrey SITA 24-2 VF. Exclusion Criteria: All Groups 1. Best-corrected visual acuity less than 20/40 2. Age \< 40 or \>85 years 3. Refractive error of \> +3.00 D or \< -7.00 D 4. Previous intraocular surgery except for uncomplicated keratorefractive surgery and cataract extraction with posterior chamber intraocular lens implantation 5. Diabetic retinopathy 6. Other diseases that may cause VF loss or optic disc abnormalities 7. Inability to clinically view or photograph the optic discs due to media opacity or poorly dilating pupil 8. Inability to perform reliably on automated VF testing 9. Life-threatening or debilitating illness making it unlikely patient could successfully complete the study. 10. Refusal of informed consent or of commitment to the full length of the study
Conditions Breast Cancer
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, multicenter study in which a serum sample will be collected at the day of starting neo adjuvant treatment in breast cancer patients

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Procedure: Blood sample — Collection of serum sample at the day of start of neo adjuvant treatment

Primary Outcomes

  • pCR rate (At 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-14
Completion: 2036-07-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Netherlands Cancer Institute
Principal Investigators:
  • Sabine Linn, MD (PRINCIPAL_INVESTIGATOR) - Antoni van Leeuwenhoek
Contact Information
Study Contact:
Sabine Linn, MD
+31205129111
s.linn@nki.nl
Ingrid Mandjes
i.mandjes@nki.nl
Sarah Pruckl, PhD
0205129111
chemosense@nki.nl
Antoni van Leeuwenhoek
Interventions
  • Procedure: Blood sample — Collection of serum sample at the day of start of neo adjuvant treatment
Study Locations (1 sites)
Antoni van Leeuwenhoek, Amsterdam, North Holland 1066CX Netherlands
Eligibility Criteria
Inclusion Criteria: * Women with a new diagnosis of triple negative breast cancer who have not yet started systemic treatment. * Patients with stage I-III disease, patient with locoregional recurrence who have not been treated with chemotherapy before. , * Aged \< 60 years * Women having a (regular) physiological menstrual cycle * Patients who are assigned to receive neoadjuvant chemotherapy with or without immunotherapy, targeted therapy and endocrine therapy * Patients must be systemic treatment naïve for current malignancy (e.g. no chemotherapy, hormonal therapy or targeted therapy) * Signed written informed consent Exclusion Criteria: * current use of hormonal contraception or in the six weeks prior to start of neoadjuvant systemic treatment for breast cancer, such as: * Oral contraception (OAC) * Hormonal intra-uterine device (IUD, Mirena) * No ovarian function suppression to preserve fertility * Other forms of hormonal contraception, including but not limited to: nuva-ring, Implanon, prikpil * Currently pregnant and / or breast feeding. In case of use of hormonal contraception or breast feeding in de last year: patients should have had at least 2 menstrual cycles since stopping hormonal contraception. \- active other malignancy * IVF-trajectory for egg cell preservation prior to start of neoadjuvant systemic treatment